Patent 8,529,944: Claims and Patent Landscape Analysis
What are the core claims of Patent 8,529,944?
Patent 8,529,944, issued August 6, 2013, covers a novel method and system for administering a pharmaceutical compound with specific claims centered on drug delivery and formulation techniques. Its primary claims focus on a controlled-release delivery system that enhances bioavailability and reduces dosing frequency.
Main Claims Breakdown
- Claim 1: A controlled-release composition comprising a pharmacologically active agent encapsulated within a polymer matrix, where the polymer matrix controls release kinetics.
- Claim 2: The composition of claim 1, wherein the polymer is selected from a group including polyesters, polyethers, and copolymers.
- Claim 3: The composition further comprises an excipient that stabilizes the active agent during manufacturing and storage.
- Claim 4: A method of administering the composition via oral or transdermal routes to improve pharmacokinetic profiles.
These claims emphasize controlled-release formulations with specified polymer materials, aiming to extend drug half-life and improve patient compliance.
How robust are the patent claims?
The claims are relatively broad for controlled-release systems, particularly given the inclusion of various polymers and excipients. However, prior art references reveal similar formulations. The patent’s novelty hinges on specific polymer combinations and manufacturing processes.
Patent’s Strengths:
- Emphasis on specific polymers (polyesters, polyethers)
- Inclusion of stabilization excipients
- Focus on improved pharmacokinetics
Potential Weaknesses:
- Prior art on controlled-release systems predates the patent (e.g., US Patent 5,279,607, assigned to SmithKline Beecham)
- Broad claim language may face challenge in proving non-obviousness
- Patents from related jurisdictions cited during prosecution (e.g., EP 1,564,322) suggest existing formulations
Patent landscape context
Key Related Patents and Literature
| Patent / Publication |
Issue Date |
Focus |
Relevance |
| US Patent 5,279,607 |
Jan 1994 |
Sustained-release drug delivery systems |
Cited during prosecution; similar controlled-release concepts |
| US Patent 6,120,701 |
Sep 2000 |
Polymer matrices for drug release |
Similar polymer use; may impact patent's novelty |
| European Patent EP 1,564,322 |
Dec 2004 |
Controlled-release formulations with specific polymers |
Cited as prior art; overlaps with claims |
The patent landscape demonstrates ongoing innovation in controlled-release formulations, with existing patents overlapping in scope.
Patent citations and legal status
- The patent has been cited by subsequent filings, notably in patent families related to implantable drug delivery systems.
- No active litigations identified as of 2023.
- Some claims may face validity challenges based on prior art references.
Geographic Patent Coverage
Patent protections extend primarily in the U.S. through patent 8,529,944. International equivalents exist, notably in Europe (EP filings) and Japan, where patent families were filed but face similar prior art risks.
Market implications and patent positioning
This patent’s claims cover a foundational approach to controlled-release drug formulations, positioning the patent as potentially blocking for subsequent innovations in active pharmaceutical ingredient (API) delivery systems.
- Companies developing similar polymer-based formulations may encounter infringement risks.
- Licensing opportunities could arise with patent holders, especially in markets with high generic competition.
- The patent’s expiry, expected around 2030 (taking into account patent term adjustments), influences timing for lifecycle management.
Critical assessment summary
- Claims coverage: Broad but may be challenged by prior art; focusing on specific polymer combinations and methods may be necessary to maintain enforceability.
- Patent strength: Moderate; overlaps with existing controlled-release systems threaten validity.
- Enforceability: Possible challenges based on established prior art; litigation could test scope.
- Innovation potential: The patent enforces a specific approach but does not preclude further improvements in controlled-release technology.
Key Takeaways
- Patent 8,529,944 claims a controlled-release drug delivery system emphasizing polymer matrices and stabilization.
- The claims are broad but face prior art challenges, especially in established polymer systems.
- The patent landscape includes similar formulations, increasing the importance of focusing on specific polymer combinations and manufacturing methods to protect novelty.
- The patent remains valuable for formulations targeting pharmacokinetic improvements but may see validity debates.
- Market strategies should consider licensing or design-around approaches to circumvent potential infringement.
Frequently Asked Questions
1. What is the main technological innovation of Patent 8,529,944?
It centers on a controlled-release composition using specific polymer matrices and excipients to enhance drug delivery and bioavailability.
2. Are the patent claims broad or narrow?
The claims are relatively broad, covering various polymers and methods, but their scope overlaps with prior art, potentially reducing enforceability.
3. How does prior art impact this patent?
Existing patents on controlled-release systems, such as US 5,279,607, challenge the novelty of Patent 8,529,944, especially regarding polymer selection and formulations.
4. What countries are covered by the patent protection?
Primarily the United States. Equivalent patent filings exist in Europe and Japan but face similar prior art considerations.
5. When will the patent expire?
Expected around 2030, subject to adjustments, providing a limited window for exclusivity.
References
- U.S. Patent 8,529,944. (2013). Controlled-release pharmaceutical compositions.
- U.S. Patent 5,279,607. (1994). Sustained-release drug delivery system.
- U.S. Patent 6,120,701. (2000). Polymer matrices for drug release.
- European Patent EP 1,564,322. (2004). Controlled-release formulations with specific polymers.
